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Abstract
Backgound: Ovarian cancer still has a relatively poor prognosis due to the frequent occurrence of drug resistance,
making the identification of new therapeutic targets an important goal. We have studied the role of HOX genes in
the survival and proliferation of ovarian cancer cells. These are a family of homeodomain-containing transcription
factors that determine cell and tissue identity in the early embryo, and have an anti-apoptotic role in a number of
malignancies including lung and renal cancer.
Methods: We used QPCR to determine HOX gene expression in normal ovary and in the ovarian cancer cell lines
SK-OV3 and OV-90. We used a short peptide, HXR9, to disrupt the formation of HOX/PBX dimers and alter
transcriptional regulation by HOX proteins.
Results: In this study we show that the ovarian cancer derived line SK-OV3, but not OV-90, exhibits highly
dysregulated expression of members of the HOX gene family. Disrupting the interaction between HOX proteins
and their co-factor PBX induces apoptosis in SK-OV3 cells and retards tumour growth in vivo.
Conclusion: HOX/PBX binding is a potential target in ovarian cancer
Background
Ovarian cancer is a relatively uncommon malignancy,
accounting for 4% of all cancers in the western world
and 5% of all cancer deaths in women, but the mortality
from this disease has improved little in the last 30 years
[1]. Detection of ovarian cancer is often at a relatively
advanced stage of the disease due to a lack of specific
symptoms, and the overall survival for women diagnosed
with stage III or IV ovarian cancer varies from 18.6-
46.7%. Treatment is usually a combination of surgery
and chemotherapy, frequently using carboplatin, but
recurrence and resistance is commonly observed with
an associated high mortality in these cases [1].
In a similar manner to other cancers, ovarian cancers
are known to over express a number of genes involved
in early development. These include the HOX genes, a
family of homeodomain-containing transcription factors
that define the identity of cells and tissues during early
development [2]. There are 39 HOX genes in mammals,
divided into four groups (A-D) in tightly linked clusters
on different chromosomes [3]. Whilst some HOX genes
have distinct functions in specific contexts, many others
have overlapping or redundant functions during early
development [4], in haematological malignancies [5],
and in a number of other cancers including melanoma
[6] and renal cancer [7], where the HOX genes have a
potent anti-apoptotic function. This redundancy in
HOX function is based in part upon the binding of
similar DNA sequences, and also on the interaction of
HOX proteins with a common set of co-factors includ-
ing PBX. PBX modifies the DNA binding specificity of
HOX proteins, influences the regulation of transcription,
and is required for many aspects of HOX function [8].
Changes in HOX gene expression have also been
observed in ovarian cancer [9-11]. Over expression of
HOXA9, HOXA10 or HOXA11 results in a serous, endo-
metrioid-like or mucinous-like phenotype respectively
[9]. In addition, HOX genes have been shown to influ-
ence the ability of ovarian cancer cells to invade other
tissues [11], and to promote tumour growth [10]. In this
s t u d yw eh a v ea d d r e s s e dw h e t h e rHOX genes have an
anti-apoptotic effect in ovarian cancer. We show that
HOX expression in the ovarian cancer cell line SK-OV3
is highly dysregulated compared to normal ovarian tis-
sue. Furthermore, interfering with HOX function using
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SK-OV3 cells both in vitro and in vivo.
Methods
Maintenance of SK-OV3 and OV-90 in culture
The human ovarian adenocarcinoma-derived cell lines
SK-OV3 and OV-90 were obtained from the American
Type Culture Collection (LGC Promochem, Teddington,
UK). The cells were cultured in McCoy’s5 Am o d i f i e d
medium (Sigma, Poole, UK) supplemented with 10%
(v/v) heat-inactivated foetal bovine serum (Invitrogen
Ltd, Paisley, UK) and 1% penicillin (10,000 U/ml)/
streptomycin (10 mg/ml) (Sigma). Cell cultures were
maintained at 37°C in a humidified, 5% CO2 incubator.
Semi quantitative PCR
Total RNA from normal human ovary tissue was pur-
chased from Applied Biosystems (Warrington, UK).
RNA was isolated from SK-OV3 and OV-90 cells using
the RNeasy® Plus Mini Kit (Qiagen Ltd, Crawley, UK)
according to the manufacturer’s instructions. cDNA was
synthesised from RNA using the Cloned AMV First
Strand Synthesis Kit (Invitrogen) following the manufac-
turer’s protocol. Semi-quantitative RT-PCR was per-
formed using the Stratagene MX3005P Real Time PCR
machine (Agilent Technologies UK Ltd, Stockport, UK)
and SYBR® Green JumpStart™ Taq ReadyMix™ (Sigma).
Oligonucleotide primers were designed to facilitate the
unique amplification of b-actin, c-Fos and each HOX
gene. Relative expression was calculated using the Livak
comparative Ct method (2
-ΔΔCt) [10].
Analysis of cell death and apoptosis
Cell viability was measured via the MTS assay (Promega,
Southampton, UK) according to the manufacturer’s
instructions. Briefly, cells were plated in a 96-well plate
at a concentration of 1 × 10
5 cells/ml and incubated for
24 hours. Cells were treated overnight with the active
peptide HXR9 or the control peptide CXR9 at a range
of dilutions. The IC50 of the cells was determined by
plotting a dose-response curve. To detect morphological
changes consistent with apoptosis, cells were harvested
by incubating in trypsin-EDTA (Sigma) at 37°C until
detached and dissociated. Apoptotic cells were identified
using a Beckman Coulter Epics XL flow cytometer
(argon laser, excitation wavelength 488 nm, FL-2 and
FL-4 detectors) and the Annexin V-PE apoptosis detec-
tion kit (BD Pharmingen).
Imaging of the cells
For phase contrast micrographs, cells were plated into
60 mm tissue culture dishes at a concentration of 1 ×
10
5 cells/ml and incubated at 37°C for 24 hours. Cells
were treated overnight with HXR9 (120 μM) or CXR9
(120 μM). The cells were washed twice with PBS, visua-
lised using a Nikon Eclipse TE100 inverted microscope
and images recorded using aN i k o nD S - Lc a m e r aa n d
capture software (Nikon Instruments Europe B.V.,
Amstelveen, The Netherlands).
For fluorescent images of HXR9 localisation, 35 mm
culture dishes were seeded with 2 × 10
5 cells and incu-
bated as previously described. The cultures were treated
with HXR9-FITC conjugate (30 μM) for 1 hour. The
cells were fixed with 10% formalin in neutral-buffered
saline (Sigma). Cells were visualised using a Nikon
Eclipse TE 2000-S fluorescent microscope and images
recorded using a DMX 1200F camera and NIS Elements
capture software (Nikon Instruments).
Detection of PARP cleavage by western blotting
SK-OV3 cells were seeded at a concentration of 4 × 10
4
cells/ml on 60 mm tissue culture dishes and were incu-
bated at 37°C. When cells approached 75% confluence,
cultures were treated overnight with HXR9 (120 μM) or
CXR9 (120 μM). Lysates were prepared with RIPA buf-
fer containing protease and phosphatase inhibitor cock-
tails and EDTA (Perbio Science UK Ltd, Cramlington,
UK). The protein concentration was quantified using
the bicinchoninic acid assay (Perbio) according to the
manufacturer’s instructions. Proteins were resolved by
10% SDS-polyacrylamide gel electrophoresis and trans-
ferred to polyvinylidene fluoride membrane. Anti-PARP
antibody (Biomol International, Exeter, UK) was used to
detect both cleaved and full-length PARP. To visualise
proteins, the ECL Western blotting detection system
(Amersham Biosciences, Little Chalfont, UK) was used.
Mice and in vivo trial
All animal experiments were conducted in accordance
with the United Kingdom Co-ordinating Committee on
Cancer Research (UKCCCR) guidelines for the Welfare
of Animals in Experimental Neoplasia [12] and approved
by the St. George’s Hospital Medical School Ethical
Review Committee. The mice were kept in positive pres-
sure isolators in 12 hour light/dark cycles and food and
water were available ad libitum.
A t h y m i cn u d em i c ew e r ei n o c u l a t e ds u b c u t a n e o u s l y
with a suspension of 2.5 × 10
6 SK-OV3 cells in culture
media (100 μl). Once tumours reached volumes of
approximately 100 mm
3, mice received an initial dose of
100 mg/Kg CXR9 or HXR9 intravenously, with subse-
quent dosing of 10 mg/Kg twice weekly. Each treatment
group contained 10 mice. The mice were monitored
carefully for signs of distress, including behavioural
changes and weight loss.
An additional 10 mice were included in each treat-
ment group to allow the amount of HXR9 peptide in
tumours to be assessed. Tumours were excised from
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of 100 mg/Kg HXR9. Total cellular protein was
extracted and 10 μg were dot blotted on nitrocellulose
membrane and probed with a rabbit polyclonal anti-
HXR9 antibody. Quantification was achieved using a
standard series of HXR9 dilutions.
Statistical analysis
Data are given as means ± SEM of at least three inde-
pendent experiments. Significant effects were deter-
m i n e db y2 - t a i l e dS t u d e n t ’s t tests (p < 0.05), or the
Mann-Whitney test for mouse tumour modelling
experiments. For the analysis of the QPCR for HOX
gene expression the Bonferroni correction was applied
to account for multiple comparisons. There are 39 HOX
genes thus the limit for a significant result is p < 0.0013.
Results
Hox gene expression in normal ovarian tissue and
ovarian cancer cell lines
Previous studies have examined the expression of HOX
genes in ovarian tumours but to date this had not been
done in a comprehensive manner, looking at all 39
members of this family. Thus, we measured the relative
expression of HOX genes in normal ovarian tissue and
in the derived cell lines SK-OV3 and OV-90 using
semi-quantitative PCR (Fig 1). This revealed that multi-
ple HOX genes had a dysregulated pattern of expression
in SK-OV3 cells, but generally not in OV-90 cells, in
comparison to the normal ovary. In SK-OV3 the
A family of the HOX genes showed a statistically signifi-
cant up regulation of HOXA5, HOXA9,a n dHOXA13.
The HOXB and HOXD families were mainly expressed
Figure 1 HOX gene expression in normal ovary and in the ovarian cancer derived cell lines SK-OV3 and OV-90 cells.G e n e
expression was determined by QPCR and expressed as a ratio to the amount of expression of the housekeeping gene, b-actin. Abbreviations
are used for each HOX gene shown on the x-axis such that, for example, HOXA1 is represented by ‘A1’. SEM is indicated by the error bars.
P-values of less than 0.0013 (Bonferroni correction for multiple hypothesis testing) for expression in SK-OV3 cells compared to that in normal
ovary are denoted *.
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showed significantly increased expression.
Targeting HOX/PBX dimers in SK-OV3 and OV-90
Results from previous studies [9,11] together with our
data show that many HOX genes are upregulated in
ovarian cancer. We therefore decided to study the role
of HOX genes in SK-OV3 and OV-90 cells by interfer-
ing with HOX function. Previous work has shown that
disrupting the interaction between HOX proteins and
their PBX co-factor can trigger apoptosis in melanoma
and renal cancer cells [6,7]. PBX binding to HOX modi-
fies the selection of DNA binding sites and hence the
identity of HOX target genes. A short peptide, HXR9,
was previously shown to disrupt the formation of HOX/
PBX dimers, alter transcriptional regulation by HOX
proteins and thereby induce apoptosis [6,7]. HXR9 con-
tains nine repeated arginine residues to facilitate cellular
uptake, probably through endocytosis [13]. In order to
show that HXR9 was able to enter cells, SK-OV3 cul-
tures were incubated with a fluorescently labelled ver-
sion of the peptide. This indicated that HXR9 was
indeed taken up by SK-OV3 cells and tended to accu-
mulate in the nucleus (Fig 2). Furthermore, HXR9 killed
SK-OV3 cells with an IC50 of approximately 70 μM,
although it did not kill OV-90 cells (Fig 3a). Cell death
in SK-OV3 cells was accompanied by characteristic
changes in cellular morphology (Fig 3b).
HXR9 treatment causes apoptosis
Flow cytometric analysis was used to distinguish
between apoptotic and necrotic cell death. SK-OV3 cells
were stained with Annexin-V-PE to detect the externali-
sation of phosphatidylserine, which occurs during the
early stages of apoptosis. Cells were counterstained with
the vital dye 7AAD. When compared with controls, a
significantly higher proportion of SK-OV3 cells treated
w i t hH X R 9w e r es h o w nt ob ei nl a t ea p o p t o s i s( P <
0.001) but few cells were found to be in the early apop-
totic or necrotic state (Fig 4).
Further, immunoblotting indicated that there was a
reduction in full-length PARP in HXR9-treated SK-OV3
cells (Fig 5); PARP cleavage is another characteristic
event of apoptosis [14].
Previous studies have shown that upregulation of cFos
is a key event in HXR9-mediated apoptosis in both mel-
anoma and renal cancer cells [6,7]. Semi-quantitative
PCR revealed that cFos expression is on average 50
times greater in SK-OV3 cells treated with HXR9 (Fig
6) than in either untreated or CXR9-treated cells, whilst
HXR9 treatment of OV-90 cells did not cause a signifi-
cant increase in cFos expression (Fig 6).
HXR9 retards tumour growth in vivo
In order to assess the efficacy of HXR9 in vivo we estab-
l i s h e dax e n o g r a f tm o d e lo fS K - O V 3i nn u d em i c eb y
injecting cells into the flank. When the average tumour
volume had reached 100 mm
3 mice were given an initial
dose of HXR9 of 100 mg/Kg iv,f o l l o w e db yt w i c e
weekly iv treatments at 10 mg/Kg. Tumour growth in
HXR9 treated mice was retarded by 46% at 32 days
compared to the control group (Fig 7a). RNA was
Figure 2 Uptake of fluorescently labelled HXR9 by SK-OV3 cells. Cells were incubated for one hour with an HXR9-FITC conjugate (30 μM)
(green). HXR9 is confined to the nucleus in the majority of cells.
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Page 4 of 9Figure 3 (a) HXR9 toxicity was determined using the MTS assay. SK-OV3 and OV-90 cells were treated overnight with 30, 60, 90 and 120 μM
of either CXR9 or HXR9. A sample of the same cell suspension was used as a “cell-only” control. Results here are presented as an average of
three independent experiments ± SEM. The IC50 for SK-OV3 was estimated from the graph to be 70 μM, no value could be determined for
OV-90. (b) Phase contrast micrographs of SKOV-3 cells treated overnight with 60 μM of HXR9 or CXR9. In HXR9 treated cultures, fewer number of
adherent cells were evident and many detached, dead cells were apparent. (×120 magnification)
Figure 4 Fluorescence activated cell sorter (FACS) analysis of Annexin V-PE stained SK-OV3 cells. Induction of apoptosis in SK-OV3 cells
treated overnight with HXR9 or CXR9 (120 μM) was compared with untreated cells. The results are presented as mean values ± SEM of five
independent experiments. ** indicates a significant difference between treatment groups, p < 0.001.
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Page 5 of 9Figure 5 PARP cleavage induced by HXR9. Lysates of CXR9-treated and HXR9-treated SK-OV3 cells were probed with an anti-PARP antibody.
A lysate of etoposide treated HL60 leukaemia cells was included as a positive control. Lane 1 - untreated HL60 cells, Lane 2- etoposide treated
HL60 cells, Lane 3 - CXR9 treated SK-OV3 cells, Lane 4 - HXR9 treated SK-OV3 cells. ‘PARP’ - position of full length PARP protein (116kDa), ‘PARP
(c)’ - position of cleaved PARP (85kDa). Beta-actin is included as a loading control.
Figure 6 c-Fos expression is elevated after treatment with HXR9. SK-OV3 and OV-90 cells were incubated for 24 hours with 120 μM HXR9
or CXR9 and cFos expression was analysed by RT-QPCR. RNA was also extracted from SK-OV3 tumours excised from mice treated twice weekly
with HXR9 (10 mg/Kg)iv, after an initial dose of 100 mg/Kg iv on day 3. Results are presented as a ratio with beta-actin expression (x1000). A very
high increase in transcription of c-Fos in HXR9 treated SK-OV3 cells and tumours was observed. Error bars represent the standard error of the
mean for three independent experiments (cell lines) or for three tumours (in vivo model).
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to measure cFos expression by QPCR; cFos was found to
be expressed at an 18-fold higher level in tumours from
HXR9 treated mice than in tumours from untreated
mice (Fig 6).
The uptake of HXR9 by tumours after the initial dose
was measured by excising tumours at 4, 12 and 24
hours and assessing the amount of HXR9 using an anti-
HXR9 antibody. This indicated that there is a rapid
accumulation of peptide in the first four hours and that
the amount of peptide remains stable beyond 24 hours
(Fig 7b).
Discussion
It is becoming increasingly apparent that HOX genes are
frequently dysregulated in different malignancies [15-17]
including renal [7], bladder [18], prostate [19,20], lung
[21] and ovarian cancer [9-11] (this study). The exact
pattern of HOX expression varies for different malignan-
cies and the significance of this is worthy of further
Figure 7 (a) HXR9 retards SK-OV3 tumour growth in mice. Mice were treated twice weekly with HXR9 (10 mg/Kg)iv, after an initial dose of
100 mg/Kg iv when the mean tumour volume reached 100 mm
3. Error bars represent the SEM for each data point. * indicates a significant
difference between treatment groups, p < 0.05 (Mann-Whitney test). (b) HXR9 accumulation in SK-OV3 tumours. Tumours were removed from
mice at 4 hours, 12 hours and 24 hours after an initial dose of HXR9 at 100 mg/Kg iv and the amount of HXR9 in the tumour tissue was
assessed using dot blotting with an anti-HXR9 antibody.
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nal expression of HOX genes in the embryonic cells, in
which case the HOX expression profile would influence
the phenotype of each cancer. There is clear evidence
for this in ovarian cancer where the expression of
HOXA9, HOXA10 or HOXA11 confer a serous, endome-
trioid-like and mucinous-like phenotype respectively [9].
It is also clear that the over-expression of some HOX
genes is directly related to the degree of malignancy, for
example elevated expression of HOXC8 is correlated
with the loss of differentiation of prostate tumours [20],
although our data indicate that HOXC8 is actually
expressed at a lower level in the ovarian cancer lines
SK-OV3 and OV-90 as compared to normal ovarian tis-
sue. In addition, loss of HOXA5 and HOXA9 expression
is generally associated with an increased resistance to
apoptosis and tumour survival [22], although both of
these genes are expressed at relatively high levels in SK-
OV3 compared to normal ovarian tissue and OV-90.
However, recent studies have shown that HOXA9
expression increases considerably in advanced stages of
ovarian cancer, indicating that it may have a different
function as the disease progresses [23]. The other HOX
genes that are notably upregulated in SK-OV3 cells (but
generally not OV-90 cells) have previously been shown
to be upregulated in other cancers, including HOXA13
[24], HOXB5 [23], HOXB9 [25] and HOXD9 [26].
One difficulty in interpreting this data is that, in gen-
eral, there is a high level of redundancy in HOX func-
tion which may mask the contribution of any of these
individual genes to a malignant phenotype. Hence a
post-translational approach may reveal more about glo-
bal HOX functions in cancer. The HXR9 peptide blocks
the binding of HOX proteins to their PBX co-factor and
in doing so alters the way in which they bind to DNA
and hence changes the regulation of their target genes
[6,7]. HXR9 causes melanoma and renal cancer cells to
undergo apoptosis, and here we have shown that the
SK-OV3 cell line derived from an ovarian tumour
r e s p o n d si nt h es a m ew a y ,i n d i c a t i n gt h a tt h eH O X /
PBX interaction is a potential target in ovarian cancer
therapy. Interestingly, HXR9 does not induce cell death
in OV-90 cells that generally do not show dysregulated
HOX expression.
T h er o l eo fHOX genes in early development is highly
conserved [2]. They may also have a common role in
malignant cells, as evidenced by a common sensitivity to
HXR9 and in similar transcriptional responses, including
the upregulation of cFos. This change in cFos expression
was previously shown to be responsible, at least in part,
for the induction of apoptosis [6]. Recent studies have
shown that cFos transcriptionally represses the key anti-
apoptotic gene c-FLIP(L), greatly sensitising prostate
cancer cells to TRAIL-induced apoptosis [27,28].
Conclusions
Novel targets are needed in ovarian cancer therapy as
the long term survival of patients is poor despite the
trial of numerous chemotherapeutic regimes including
the current standard of care, carboplatin/paclitaxel
[1,29]. The HOX genes are independent of the targets of
current chemotherapeutics (as far as this can be
known), and hence targeting the HOX/PBX interaction
is a potential alternative or addition to current therapeu-
tics when drug resistance develops.
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